Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The proportion of prescribing Saxenda (liraglutide approved for weight management) dropped from 79% in 2018 to 9% in 2023 while in 2023 Wegovy (recieved FDA approval in 2020) was prescribed for 60% of GLP-1 RA users in non-diabetics with obesity/overweight diagnosis
This activation results in several beneficial effects mimicking the hormone's natural functions
I will continue with my treatment and many more products
Not for human consumption, veterinary use, or diagnostic purposes.
The requirement of coverage for at least one GLP-1 drug from every FEHB plan remains true for each EGWP
GLP-1 medications are not controlled substances, which works in your favor
US$ 21.15
US$ 21.65
US$ 23.72
US$ 29.21
